HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Drugs, 340B, and the Challenges of Implementing Health Reform

This article was originally published in RPM Report

Executive Summary

A proposed rule issued by HRSA probably changes prescription drug spending in the US by about .005%. But it will have an impact on almost every pharmaceutical company pricing department, and offers a valuable illustration of some of the bigger themes of implementing the reform law overall.

Related Content

Price Controls in Action: Understanding the Rise of the 340B Program
Second-Guessing FDA: CMS' Expanding Regulatory Role
340B: A Test Market for Health Care Reform?
Health Care Reform and Business Development: 10 Reasons It Matters





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts